secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001664710-24-000099
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF
--------------------------------------------------------------------------------

- 55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.
- 31.4% (16/51) of high-transfusion-burden MDS patients achieved TI >=8 weeks; 50% of those had TI >=24 weeks.
- In MF, 63.4% (26/41) of transfusion-dependent patients had reduced RBC burden; 24.4% achieved TI.
- 40% (8/20) of MF patients with baseline spleen >=450 cm³ had spleen volume reduction at week 24; 3 had >=35% reduction.
- Elritercept generally well-tolerated; Phase 3 RENEW trial in MDS expected to begin enrollment soon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000099/0001664710-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000099/kros-20241209.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer